1. In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal

DOCUMENT DESCRIPTION

In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal junction (GEJ) adenocarcinoma. We expect that major-market sales will rapidly increase over the forecast period, totaling almost $9.5 billion in 2025. This growth will be predominantly fuelled by the approval of seven agents in the indication, and also by Cyramza (Eli Lilly?s ramucirumab).

The entry of three PD-1/PD-L1 inhibitors into the gastric and GEJ adenocarcinoma market (Merck & Co.?s Keytruda [pembrolizumab], Bristol Myers-Squibb/Ono Pharmaceutical?s Opdivo [nivolumab], and Merck KGaA/Pfizer?s avelumab) will significantly drive growth during the forecast period. We also forecast the approval of Yervoy (Bristol Myers-Squibb/Ono Pharmaceutical?s ipilimumumab) to be used in conjunction with Opdivo. In addition, we anticipate the launch of a next generation HER2-targeting therapy (Roche/Genentech/Chugai?s Perjeta [pertuzumab]), a cancer 'stemness' inhibitor (Boston Biomedical?s napabucasin), and a MMP-9 inhibitor (Gilead Sciences? GS-5745). Collectively, these agents will contribute 80% of total sales in the gastric and GEJ adenocarcinoma in 2025.


Introduction
Key Findings
Market Share of Gastric Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at [email protected] or ask the author directly by using the form to the right. If you cannot view the preview above this document description, go here to view the large preview instead.